Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice

Traditional NSAIDs, selective cyclooxygenase (COX)-2 inhibitors, and inhibitors of nitric oxide synthase (NOS) impair the healing of preexisting gastric ulcers. However, the role of COX-1 (with or without impairment of COX-2) and the interaction between COX and NOS isoforms during healing are less clear. Thus we investigated healing and regulation of COX and NOS isoforms during ulcer healing in COX-1 and COX-2 deficiency and inhibition mouse models. In this study, female wild-type COX-1(-/-) and COX-2(-/-) mice with gastric ulcers induced by cryoprobe were treated intragastrically with vehicle, selective COX-1 (SC-560), COX-2 (celecoxib, rofecoxib, and valdedoxib), and unselective COX (piroxicam) inhibitors. Ulcer healing parameters, mRNA expression, and activity of COX and NOS were quantified. Gene disruption or inhibition of COX-1 did not impair ulcer healing. In contrast, COX-2 gene disruption and COX-2 inhibitors moderately impaired wound healing. More severe healing impairment was found in dual (SC-560 + rofecoxib) and unselective (piroxicam) COX inhibition and combined COX impairment (in COX-1(-/-) mice with COX-2 inhibition and COX-2(-/-) mice with COX-1 inhibition). In the ulcerated repair tissue, COX-2 mRNA in COX-1(-/-) mice, COX-1 mRNA in COX-2(-/-) mice, and, remarkably, NOS-2 and NOS-3 mRNA in COX-impaired mice were more upregulated than in wild-type mice. This study demonstrates that COX-2 is a key mediator in gastric wound healing. In contrast, COX-1 has no significant role in healing when COX-2 is unimpaired but becomes important when COX-2 is impaired. As counterregulatory mechanisms, mRNA of COX and NOS isoforms were increased during healing in COX-impaired mice.

Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial

BACKGROUND The long-term results after second generation everolimus eluting bioresorbable vascular scaffold (Absorb BVS) placement in small vessels are unknown. Therefore, we investigated the impact of vessel size on long-term outcomes, after Absorb BVS implantation. METHODS In ABSORB Cohort B Trial, out of the total study population (101 patients), 45 patients were assigned to undergo 6-month and 2-year angiographic follow-up (Cohort B1) and 56 patients to have angiographic follow-up at 1-year (Cohort B2). The pre-reference vessel diameter (RVD) was <2.5 mm (small-vessel group) in 41 patients (41 lesions) and ≥2.5 mm (large-vessel group) in 60 patients (61 lesions). Outcomes were compared according to pre-RVD. RESULTS At 2-year angiographic follow-up no differences in late lumen loss (0.29±0.16 mm vs 0.25±0.22 mm, p=0.4391), and in-segment binary restenosis (5.3% vs 5.3% p=1.0000) were demonstrated between groups. In the small-vessel group, intravascular ultrasound analysis showed a significant increase in vessel area (12.25±3.47 mm(2) vs 13.09±3.38 mm(2) p=0.0015), scaffold area (5.76±0.96 mm(2) vs 6.41±1.30 mm(2) p=0.0008) and lumen area (5.71±0.98 mm(2) vs 6.20±1.27 mm(2) p=0.0155) between 6-months and 2-year follow-up. No differences in plaque composition were reported between groups at either time point. At 2-year clinical follow-up, no differences in ischaemia-driven major adverse cardiac events (7.3% vs 10.2%, p=0.7335), myocardial infarction (4.9% vs 1.7%, p=0.5662) or ischaemia-driven target lesion revascularisation (2.4% vs 8.5%, p=0.3962) were reported between small and large vessels. No deaths or scaffold thrombosis were observed. CONCLUSIONS Similar clinical and angiographic outcomes at 2-year follow-up were reported in small and large vessel groups. A significant late lumen enlargement and positive vessel remodelling were observed in small vessels.

The Hydroxyl Side Chain of a Highly Conserved Serine Residue Is Required for Cation Selectivity and Substrate Transport in the Glial Glutamate Transporter GLT-1/SLC1A2

Glutamate transporters maintain synaptic concentration of the excitatory neurotransmitter below neurotoxic levels. Their transport cycle consists of cotransport of glutamate with three sodium ions and one proton, followed by countertransport of potassium. Structural studies proposed that a highly conserved serine located in the binding pocket of the homologous GltPh coordinates l-aspartate as well as the sodium ion Na1. To experimentally validate these findings, we generated and characterized several mutants of the corresponding serine residue, Ser-364, of human glutamate transporter SLC1A2 (solute carrier family 1 member 2), also known as glutamate transporter GLT-1 and excitatory amino acid transporter EAAT2. S364T, S364A, S364C, S364N, and S364D were expressed in HEK cells and Xenopus laevis oocytes to measure radioactive substrate transport and transport currents, respectively. All mutants exhibited similar plasma membrane expression when compared with WT SLC1A2, but substitutions of serine by aspartate or asparagine completely abolished substrate transport. On the other hand, the threonine mutant, which is a more conservative mutation, exhibited similar substrate selectivity, substrate and sodium affinities as WT but a lower selectivity for Na(+) over Li(+). S364A and S364C exhibited drastically reduced affinities for each substrate and enhanced selectivity for l-aspartate over d-aspartate and l-glutamate, and lost their selectivity for Na(+) over Li(+). Furthermore, we extended the analysis of our experimental observations using molecular dynamics simulations. Altogether, our findings confirm a pivotal role of the serine 364, and more precisely its hydroxyl group, in coupling sodium and substrate fluxes.

Na 50 Nachlass Arthur Schopenhauer - 'Schopenhauer-Archiv', 290 - Dankesschreiben an den Professor Hugo von Meltzl wegen Zusendung der Publikation "Akademische philosophische Sänge und Klänge"

u.a.: Burschenschaft; Julius Frauenstädt;

Ms.Ff.F.Stoltze 3. 290 - Brief von Joseph Schmölder an Friedrich Stoltze

Tod Alois Henningers

Fragm. germ. II 1 - Mystischer Text (Über den Empfang der Eucharistie)

Trägerband der Blattreste: Inc. oct. 290; Trägerband der Doppelblätter nicht bekannt; Vorbesitzer: Johannes Lenglin; Dominikanerkloster Frankfurt am Main

Na 1 Nachlass Max Horkheimer, 637 - "Art and Mass Culture" (p. IX 14.1-2)

"Art and Mass Culture" (GS 4, S. 419-438); 1. Aufsatz, veröffentlicht in: SPSS IX, 1941, S. 290-304; 2. Exzerpt aus: Mortimer Adler, "Art and Prudence", Part II und VI. Typoskript mit handschriftlichen Korrekturen. 18 Blatt;

Na 1 Nachlass Max Horkheimer, 801 - "Dialektik der Aufklärung" von Max Horkheimer und Theodor W. Adorno (p. XI 6.1 - XI 6.2a)

[GS 5, S. 13-290]. Aufzeichnungen und Entwürfe, 1939-1946; veröffentlicht in Amsterdam, 1947:; 1. "Philosophische Fragmente", published by the Institute of Social Research, New York City, 1944. Als Typoskript vervielfältigt, 320 S., gebunden; 2. Aus der "Dialektik der Aufklärung"; Kapitel: "Begriff der Aufklärung":; 2a) Typoskript mit deutschen Titel "Mythos und Aufklärung", 53 Blatt (2 Exemplare); 2b) Entwürfe und Teilstücke, Typoskript mit eigenen Korrekturen von Theodor W. Adorno, 11 Blatt; 2c) Gliederungspunkte zum Kapitel "Begriff der Aufklärung", hier noch mit dem Titel "Mythologie und Aufklärung", Typoskript mit eigenen Ergänzungen von Max Horkheimer, 3 Blatt; 2d) "Zur Frage der Grenze der Entmythologisierung", Entwurf, Typoskript mit eigenen Ergänzungen von Theodor W. Adorno, 1 Blatt; 2e) "Aufklärung mythisch", Entwurf, Typoskript mit eigenen Korrekturen und Ergänzungen, 1 Blatt; 2f) Entwurf des Anfangs des Kapitels "Begriff der Aufklärung", 1 Heft, 16 Blatt, davon 8 leer; 2g) Max Horkheimer und Theodor W. Adorno: Eigene Notizen zum Begriff der Aufklärung, 12 Blatt;